4D Path

4D Path develops precision oncology diagnostics powered by its groundbreaking QPOR (Quantitative Pathology-Omic Response) Platform, designed to directly measure and quantify cell cycle deregulations and tumor microenvironment dynamics to predict a patient's response to cancer therapy. The platform was created based on the insight that most cancer treatments target different phases of the cell cycle, yet without tools to characterize cell cycle dysfunction at the individual patient level, many treatments fall short of providing truly personalized care. The QPOR Platform provides unprecedented understanding of the tumor state by measuring and quantifying cell cycle deregulations and tumor microenvironment dynamics, unlocking valuable insights into the collective tumor state. It aims to deliver precise predictions of tumor response to therapy, helping researchers and clinicians understand which treatment most effectively targets the cell cycle deregulations found in a patient's tumor. The platform has been validated in clinical studies, demonstrating improved therapeutic response prediction across multiple tumor types, different therapeutic classes, and in both clinical trial and real-world settings. 4D Path partners with pharmaceutical companies and researchers to deliver customized treatment prediction signatures for therapies of interest, enabling companion diagnostic development for precision medicine. Founded in 2016 and headquartered in Boston, Massachusetts, 4D Path has raised approximately $17.1 million in a Series B round.

Oncology > Drugs > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine

College Wise > Massachusetts Institute of Technology, University of Cambridge